EyePoint Pharmaceuticals Reports the First Patient Dosing in P-III (LUGANO) Study of Duravyu to Treat Wet Age-Related Macular Degeneration
Shots:
- EyePoint has dosed the first patient with Duravyu under the P-III (LUGANO) study for treating wet age-related macular degeneration (wet AMD). It is also being assessed under P-III (LUCIA) trial with first patient dosing planned in YE’24 and P-II (VERONA) study for DME with topline data in Q1’25
- The studies will assess the safety & efficacy of Duravyu vs aflibercept in wet AMD patients both naïve and experienced, each recruiting ~400 subjects worldwide. Patients will be administered an intravitreal injection, Q6M, beginning from 2nd month
- The 1EP of the studies include the change in BCVA at wks.52 and 56, while 2EPs are safety, reduced treatment burden, percentage of eyes without additional aflibercept & OCT-measured anatomical outcomes. Topline data is expected in 2026
Ref: EyePoint | Image: EyePoint
Related News:- EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
